Literature DB >> 28872304

Development of an Azo-Based Photosensitizer Activated under Mild Hypoxia for Photodynamic Therapy.

Wen Piao1, Kenjiro Hanaoka1, Tomotsumi Fujisawa2, Satoshi Takeuchi2,3, Toru Komatsu1,4, Tasuku Ueno1, Takuya Terai1, Tahei Tahara2,3, Tetsuo Nagano5, Yasuteru Urano1,6,7.   

Abstract

Photodynamic therapy (PDT) utilizes photoirradiation in the presence of photosensitizers to ablate cancer cells via generation of singlet oxygen (1O2), but it is important to minimize concomitant injury to normal tissues. One approach for achieving this is to use activatable photosensitizers that can generate 1O2 only under specific conditions. Here, we report a novel photosensitizer that is selectively activated under hypoxia, a common condition in solid tumors. We found that introducing an azo moiety into the conjugated system of a seleno-rosamine dye effectively hinders the intersystem crossing process that leads to 1O2 generation. We show that the azo group is reductively cleaved in cells under hypoxia, enabling production of 1O2 to occur. In PDT in vitro, cells under mild hypoxia, within the range typically found in solid tumors (up to about 5% O2), were selectively ablated, leaving adjacent normoxic cells intact. This simple and practical azo-based strategy should be widely applicable to design a range of activatable photosensitizers.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28872304     DOI: 10.1021/jacs.7b05019

Source DB:  PubMed          Journal:  J Am Chem Soc        ISSN: 0002-7863            Impact factor:   15.419


  21 in total

1.  Imaging GPCR internalization using near-infrared Nebraska red-based reagents.

Authors:  Lauren Lesiak; Xinqi Zhou; Yuan Fang; Jia Zhao; Jon R Beck; Cliff I Stains
Journal:  Org Biomol Chem       Date:  2020-04-01       Impact factor: 3.876

2.  Photophysical Properties of New Pyrazolone Based Azo- Compounds.

Authors:  Emine Bagdatli; Derya Yaman
Journal:  J Fluoresc       Date:  2019-12-17       Impact factor: 2.217

3.  Synthesis of Rhodamines and Rosamines Using 3,6-Difluoroxanthone as a Common Intermediate.

Authors:  Carlos Arambula; Joseph Rodrigues; Jung Jae Koh; Zachary Woydziak
Journal:  J Org Chem       Date:  2021-11-24       Impact factor: 4.354

4.  A host-guest strategy for converting the photodynamic agents from a singlet oxygen generator to a superoxide radical generator.

Authors:  Kun-Xu Teng; Li-Ya Niu; Qing-Zheng Yang
Journal:  Chem Sci       Date:  2022-04-23       Impact factor: 9.969

5.  Phosphinate-containing rhodol and fluorescein scaffolds for the development of bioprobes.

Authors:  Yuan Fang; Gillian N Good; Xinqi Zhou; Cliff I Stains
Journal:  Chem Commun (Camb)       Date:  2019-05-03       Impact factor: 6.222

Review 6.  Photodynamic Therapy and the Biophysics of the Tumor Microenvironment.

Authors:  Aaron J Sorrin; Mustafa Kemal Ruhi; Nathaniel A Ferlic; Vida Karimnia; William J Polacheck; Jonathan P Celli; Huang-Chiao Huang; Imran Rizvi
Journal:  Photochem Photobiol       Date:  2020-03-05       Impact factor: 3.421

Review 7.  Fighting Hypoxia to Improve PDT.

Authors:  Ludivine Larue; Bauyrzhan Myrzakhmetov; Amina Ben-Mihoub; Albert Moussaron; Noémie Thomas; Philippe Arnoux; Francis Baros; Régis Vanderesse; Samir Acherar; Céline Frochot
Journal:  Pharmaceuticals (Basel)       Date:  2019-10-30

8.  Novel oligopeptide nanoprobe for targeted cancer cell imaging.

Authors:  Wen-Qiang Ding; Si-Yong Qin; Yin-Jia Cheng; Yi-Han Ma; Ai-Qing Zhang
Journal:  RSC Adv       Date:  2018-09-03       Impact factor: 3.361

9.  Rational design of a "dual lock-and-key" supramolecular photosensitizer based on aromatic nucleophilic substitution for specific and enhanced photodynamic therapy.

Authors:  Kun-Xu Teng; Li-Ya Niu; Yan-Fei Kang; Qing-Zheng Yang
Journal:  Chem Sci       Date:  2020-08-25       Impact factor: 9.825

Review 10.  Chemodynamic nanomaterials for cancer theranostics.

Authors:  Jingqi Xin; Caiting Deng; Omer Aras; Mengjiao Zhou; Chunsheng Wu; Feifei An
Journal:  J Nanobiotechnology       Date:  2021-06-28       Impact factor: 10.435

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.